<scp>pH</scp>‐Sensitive stimulus‐responsive nanocarriers for targeted delivery of therapeutic agents

Karimi, Mahdi; Eslami, Masoud; Zangabad, Parham Sahandi; Mirab, Fereshtehsadat; Farajisafiloo, Negar; Shafaei, Zahra; Ghosh, Deepanjan; Bozorgomid, Mahnaz; Dashkhaneh, Fariba; Hamblin, Michael R.

doi:10.1002/wnan.1389

Cited by 185 publications

(107 citation statements)

References 149 publications

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…In addition, here, the exploitation of chemical cross-linking hinders disassembly of the hydrophilic chains in aqueous conditions. 255 …”

Section: Challenges Perspectives and Critical Remarksmentioning

confidence: 99%

“…16,17 In DDSs, various basic materials can be incorporated in the design of nanocarriers such as albumin, 18 nanocarbons (e.g., carbon nanotubes (CNT), reduced graphene oxide (reduced GO), and fluorescent carbon NPs), 19–21 virus and bacteriophage-based NPs, 22,23 stimuli-responsive polymer moieties, 24–29 metal NPs, 30 and semiconductor NPs. 31 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Smart Nanostructures for Cargo Delivery: Uncaging and Activating by Light

et al. 2017

Self Cite

View full text Add to dashboard Cite

Nanotechnology has begun to play a remarkable role in various fields of science and technology. In biomedical applications, nanoparticles have opened new horizons, especially for biosensing, targeted delivery of therapeutics, and so forth. Among drug delivery systems (DDSs), smart nanocarriers that respond to specific stimuli in their environment represent a growing field. Nanoplatforms that can be activated by an external application of light can be used for a wide variety of photoactivated therapies, especially light-triggered DDSs, relying on photoisomerization, photo-cross-linking/un-cross-linking, photoreduction, and so forth. In addition, light activation has potential in photodynamic therapy, photothermal therapy, radiotherapy, protected delivery of bioactive moieties, anticancer drug delivery systems, and theranostics (i.e., real-time monitoring and tracking combined with a therapeutic action to different diseases sites and organs). Combinations of these approaches can lead to enhanced and synergistic therapies, employing light as a trigger or for activation. Nonlinear light absorption mechanisms such as two-photon absorption and photon upconversion have been employed in the design of light-responsive DDSs. The integration of a light stimulus into dual/multiresponsive nanocarriers can provide spatiotemporal controlled delivery and release of therapeutic agents, targeted and controlled nanosystems, combined delivery of two or more agents, their on-demand release under specific conditions, and so forth. Overall, light-activated nanomedicines and DDSs are expected to provide more effective therapies against serious diseases such as cancers, inflammation, infections, and cardiovascular disease with reduced side effects and will open new doors toward the treatment of patients worldwide.

show abstract

“…In addition, here, the exploitation of chemical cross-linking hinders disassembly of the hydrophilic chains in aqueous conditions. 255 …”

Section: Challenges Perspectives and Critical Remarksmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Smart Nanostructures for Cargo Delivery: Uncaging and Activating by Light

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, stimulus-responsive DDSs and gene carriers that respond to different physiological cues in diseased or cancerous tissue (e.g. the acidic microenvironment of tumors) have been extensively investigated [8,132]. The addition of stimulus-responsive moieties into the structure of albumin NPs would be a potential future research field.…”

Section: Expert Opinionmentioning

confidence: 99%

Albumin nanostructures as advanced drug delivery systems

Karimi

Bahrami

Ravari

et al. 2016

Expert Opinion on Drug Delivery

Self Cite

291

190

View full text Add to dashboard Cite

Introduction One of the biggest impacts that the nanotechnology has made on medicine and biology, has been in the area of drug delivery systems (DDSs). Many drugs suffer from serious problems concerning insolubility, instability in biological environments, poor uptake into cells and tissues, suboptimal selectivity for targets and unwanted side effects. Nanocarriers can be designed as DDSs to overcome many of these drawbacks. One of the most versatile building blocks to prepare these nanocarriers is the ubiquitous, readily available and inexpensive protein, serum albumin. Areas covered This review covers the use of different types of albumin (human, bovine, rat, and chicken egg) to prepare nanoparticle and microparticle-based structures to bind drugs. Various methods have been used to modify the albumin structure. A range of targeting ligands can be attached to the albumin that can be recognized by specific cell receptors that are expressed on target cells or tissues. Expert opinion The particular advantages of albumin used in DDSs include ready availability, ease of chemical modification, good biocompatibility, and low immunogenicity. The regulatory approvals that have been received for several albumin-based therapeutic agents suggest that this approach will continue to be successfully explored.

show abstract

“…Gold nanoparticles (AuNP) have been extensively studied in nanomedicine for their promising drug delivery applications (Karimi et al, 2016) due to their unique physicochemical and surface characteristics (Salata, 2004;Levy et al, 2010;Sasidharan and Monteiro-Riviere 2015). Upon entering a biological environment, biomolecules immediately attach to the NP surfaces to form a biocorona which imparts new properties to the NP (Lundqvist et al, 2008;Treuel and Nienhaus, 2012;Treuel et al, 2013;Walkey and Chan, 2012).…”

Section: Introductionmentioning

confidence: 99%